Canurta Exceeds ALS Fundraising Goal, Publishes Breakthrough on Cannflavin Detection, and Engages Investors at RESI Boston

We Surpassed our Fundraising Goal for Pull to End ALS and Placed Second in Challenge

Team Canurta raised a total of $4,599.07 for ALS Canada at this year's Pull to End ALS Challenge. These funds will support services and research advancement for patients and families. Our team is proud to also place second in the pull with a record time of 49 seconds!

We look forward to participating again next year.

Establishing a New Standard in Hemp Extract Analysis, Paper to be Published in October

In a significant advancement for the field of botanical drug development, Canurta, in collaboration with Applied Pharmaceutical Innovation (API), has unveiled a validated method for the detection of cannflavins in hemp extracts that exceeds the global benchmarks set by the ICH and EMA.

"The introduction of this method is emblematic of Canurta's dedication to spearheading innovation," said Akeem Gardner, Founder & CEO of Canurta. "We remain steadfast in our mission to elevate the standards of hemp extract analysis and to continually shape a future grounded in excellence and reliability."

Chatting with Early-Stage Investors at the RESI Conference in Boston

The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development.

Canurta Founder & CEO Akeem Gardner attended the Boston series between September 18-20, 2023.

Canurta's September Milestones

Research & Development

New Discovery: Canurta's Science Team discovered inhibitor activity of cannflavins against West Nile virus protease NS3 in an in vitro assay.

Manufacturing

Final Pre-Commercialization Batches: Nearing completion, with initial commercial production beginning with our contract manufacturer in the US. Natural Health Product branding in progress for initial product launches under our USA commercial brand.

Bioinformatics

Molecular Generation Project Update: We concluded the initial phase of our novel molecule generation project. Leveraging generative models, our pipeline can efficiently navigate a molecule's chemical subspace, introducing constraints for the modification of substructures. These constraints are essential, ensuring generated molecules are both theoretically viable and compatible with our proprietary biosynthesis platform.

Our platform's adaptability goes beyond flavonoids. Built on modularity, it can explore diverse chemical spaces, and will be able to choose from a selection of deep learning frameworks depending on the target. This allows for the generation, optimization, and prediction of ligands' biological properties. These molecules can undergo in vitro testing against predicted targets using our QSAR models.